Heart failure: Advances through genomics

Nature Reviews Genetics

Volumn 12, Issue 5, 2011, Pages 357-362

  Creemers, Esther E ^a   Wilde, Arthur A ^a   Pinto, Yigal M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLAMBAN;

ARTICLE; EXOME; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOMICS; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART RIGHT VENTRICLE DYSPLASIA; HOSPITALIZATION; HUMAN; HYPERTENSION; METABOLOMICS; MICROARRAY ANALYSIS; MUTATION; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REGULATORY SEQUENCE; RNA SPLICING; SARCOMERE; TRANSCRIPTOMICS;

ANIMALS; GENOMICS; HEART FAILURE; HUMANS; HYPERTENSION; MICE; MYOCARDIAL INFARCTION; TRANSCRIPTION, GENETIC;

EID: 79954932575     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg2983     Document Type: Article

References (49)

1. Hunt, S. A. et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, e391-e479 (2009).
2. Creemers, E. E. & Pinto, Y. M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 89, 265-272 (2010).
3. Swynghedauw, B. Molecular mechanisms of myocardial remodeling. Physiol. Rev 79, 215-262 (1999). (Pubitemid 29056953)
4. Benjamin, I. J. & Schneider, M. D. Learning from failure: congestive heart failure in the postgenomic age. J. Clin. Invest. 115, 495-499 (2005). (Pubitemid 40322218)
5. Mudd, J. O. & Kass, D. A. Tackling heart failure in the twenty-first century. Nature 451, 919-928 (2008). (Pubitemid 351301747)
6. Lee, D. S. et al. Association of parental heart failure with risk of heart failure in offspring. N. Engl. J. Med. 355, 138-147 (2006). (Pubitemid 44050395)
7. Smith, N. L. et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ. Cardiovasc. Genet. 3, 256-266 (2010).
8. Morrison, A. C. et al. Genomic variation associated with mortality among adults of European and african ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circ. Cardiovasc. Genet. 3, 248-255 (2010).
9. Vasan, R. S. et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA 302, 168-178 (2009).
10. Cappola, T. P. et al. Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc. Natl Acad. Sci. USA 108, 2456-2461 (2011).
11. Hershberger, R. E. et al. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J. Card. Fail. 15, 83-97 (2009).
12. van der Zwaag, P. A. et al. One mutation fits all: phospolamban R14del causes both dilated cardiomypathy and arrhytmogenic right ventricular cardiomyopathy/dysplasia. Circulation 122, A17663 (2010).
13. van Spaendonck-Zwarts, K. Y. et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 121, 2169-2175 (2010).
14. Ng, S. B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nature Genet. 42, 790-793 (2010).
15. Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002). (Pubitemid 35232291)
16. Movassagh, M. et al. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS ONE 5, e8564 (2010).
17. Yi, P., Han, Z., Li, X. & Olson, E. N. The mevalonate pathway controls heart formation in Drosophila by isoprenylation of Gγ 1. Science 313, 1301-1303 (2006). (Pubitemid 44330956)
18. Milan, D. J. et al. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 120, 553-559 (2009).
19. Lowes, B. D. et al. Myocardial gene expression in dilated cardiomyopathy treated with ß-blocking agents. N. Engl. J. Med. 346, 1357-1365 (2002). (Pubitemid 34754608)
20. Knollmann, B. C. & Roden, D. M. A genetic framework for improving arrhythmia therapy. Nature 451, 929-936 (2008). (Pubitemid 351301748)
21. Nanni, L, Romualdi, C, Maseri, A. & Lanfranchi, G. Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. J. Mol. Cell. Cardiol. 41, 934-948 (2006). (Pubitemid 44791333)
22. Hwang, J. J. et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol. Genomics 10, 31-44 (2002).
23. Schroen, B. et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ. Res. 95, 515-522 (2004). (Pubitemid 39180932)
24. Schroen, B. et al. Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. J. Exp. Med. 204, 1227-1235 (2007). (Pubitemid 46798164)
25. van Kimmenade, R. R. et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48, 1217-1224 (2006).
26. Matkovich, S. J., Zhang, Y, Van Booven, D. J. & Dorn, G. W. Deep mRNA sequencing for in vivo functional analysis of cardiac transcriptional regulators: application to Gaq. Circ. Res. 106, 1459-1467 (2010).
27. Creemers, E. E., Sutherland, L. B., Oh, J., Barbosa, A. C. & Olson, E. N. Coactivation of MEF2 by the SAP domain proteins myocardin and MASTR. Mol. Cell 23, 83-96 (2006). (Pubitemid 43963447)
28. Kong, S. W. et al. Heart failure-associated changes in RNA splicing of sarcomere genes. Circ. Cardiovasc. Genet. 3, 138-146 (2010).
29. Neagoe, C. et al. Titin isoform switch in ischemic human heart disease. Circulation 106, 1333-1341 (2002). (Pubitemid 35013035)
30. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature Biotech. 28, 511-515 (2010).
31. Kleinjan, D. A. & van Heyningen, V. Long-range control of gene expression: emerging mechanisms and disruption in disease. Am. J. Hum. Genet. 76, 8-32 (2005). (Pubitemid 40023762)
32. Blow, M. J. et al. ChIP-Seq identification of weakly conserved heart enhancers. Nature Genet. 42, 806-810 (2010).
33. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Rev Genet. 10, 32-42 (2009).
34. Rakyan, V. K. & Beck, S. Epigenetic variation and inheritance in mammals. Curr. Opin. Genet. Dev. 16, 573-577 (2006). (Pubitemid 44738519)
35. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
36. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 (2008).
37. Care, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nature Med. 13, 613-618 (2007). (Pubitemid 46828487)
38. Small, E. M., Frost, R. J. & Olson, E. N. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121, 1022-1032 (2010).
39. van Rooij, E. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579 (2007). (Pubitemid 46683138)
40. Elmen, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008). (Pubitemid 351550859)
41. Tijsen, A. J. et al. MiR423-425p as a circulating biomarker for heart failure. Circ. Res. 106, 1035-1039 (2010).
42. Clop, A. et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nature Genet 38, 813-818 (2006). (Pubitemid 43980603)
43. Kasowski, M. et al. Variation in transcription factor binding among humans. Science 328, 232-235 (2010).
44. Dorn, G. W. Pharmacogenetic profiling in the treatment of heart disease. Transl. Res. 154, 295-302 (2009).
45. Johnson, J. A. & Liggett, S. B. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin. Pharmacol. Ther. 89, 366-378 (2011).
46. Brugts, J. J. et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur. Heart J. 31, 1854-1864 (2010).
47. 2+ pump, cause Darier disease. Nature Genet. 21, 271-277 (1999). (Pubitemid 29124933)
48. Mayosi, B. M. et al. Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure. Heart 92, 105-109 (2006). (Pubitemid 43021870)
49. 2+ pumps revealed by analysis of null mutants. Ann. N. Y. Acad. Sci. 986, 453-460 (2003). (Pubitemid 36584149)